Lichen planus affects 0.5% to 2% of the population. The involvement of the oesophagus is a rare manifestation with high morbidity and risk of malignancy. Clinical characteristics and diagnostic-therapeutic strategies were reviewed. A retrospective study of clinical-pathological characteristics, endoscopic findings, and follow-up of patients with oesophageal lichen planus treated at a tertiary hospital during 2006–2023 was conducted. Nine patients (1 man, 8 women) with a median age of 76 years were included. All patients had oral lichen planus. Dysphagia was the initial symptom, being the first manifestation of the disease in 2 cases. All presented lesions in the oral oesophagus with fibrous rings, stenosis, and mucosal denudation. Histological changes of the lichenoid type were observed in 8/9. After a median follow-up of 2 years, no progression to oesophageal squamous cell carcinoma was observed. Swallowed glucocorticoid therapy, proton pump inhibitors, prokinetics, and oesophageal dilatations were prescribed. Eight out of 9 patients showed partial improvement with clinical stabilization. Oesophageal lichen planus is an infrequent and underdiagnosed disease. Its diagnosis may be based on endoscopic features, histopathology, and direct immunofluorescence. The correct management is often challenging, but necessary because this entity has been associated with oesophageal squamous cell carcinoma
Background: LMO2 is a relevant gene involved in B-cell ontogeny and a survival predictor of aggressive large B-cell lymphomas (aLBCL). Most studies assessing LMO2 mRNA expression have relied on microarray platforms or qRT-PCR methods, overlooking tissue morphology. In this study, we evaluate LMO2 RNA expression by chromogenic in situ hybridization (CISH) in normal tissue and in a series of 82 aLBCL. Methods: LMO2 CISH was performed in formalin-fixed paraffin-embedded tissues, scored by three different methods, and correlated with a transcriptome panel. Results: We obtained statistically significant results correlating the methods of evaluation with LMO2 protein expression and gene expression results. Normal tonsil tissue showed high levels of LMO2, particularly within the light zone of the germinal center. Conversely, in aLBCL, a notable reduction in LMO2 expression was noted, remarkably in cases carrying MYC rearrangements. Furthermore, significant results were obtained through overall survival and Cox regression survival analysis, incorporating International Prognostic Index data alongside LMO2 expression levels. Conclusions: We show a reliable method to identify LMO2 mRNA expression by CISH, effectively capturing many of the reported biologic features of LMO2.
An otherwise healthy 82‐year‐old woman presented with recurrent, asymptomatic erythematous papulo‐nodular lesions on the face and extremities. A skin biopsy revealed a dense, non‐epidermotropic lymphohistiocytic infiltrate with granulomatous features and a mixed population of medium‐sized atypical lymphoid cells and plasma cells. Immunohistochemistry demonstrated a predominant CD4+ T‐cell population with a T‐follicular helper (TFH) phenotype (PD1+, CXCL13+, BCL6+), admixed with EBV‐negative monotypic B‐cells. Clonality was confirmed for both T and B cells by BIOMED2 PCR, and a RHOA p.G17V mutation was identified. Next‐generation sequencing revealed additional mutations in TET2 and DNMT3A. Complete staging studies showed no nodal or visceral involvement. A minimal circulating population (0.11%) of atypical CD4+ T‐cells with surface CD3 loss and TFH markers was detected in peripheral blood. Based on clinical and histopathological findings, a diagnosis of primary cutaneous peripheral T‐cell lymphoma with TFH phenotype (pcPTCL‐TFH) was made. The patient also developed a cutaneous squamous cell carcinoma, in which a peritumoral TFH lymphoid infiltrate with the same clonal features was identified. This case illustrates the diagnostic complexity of pcPTCL‐TFH and its potential overlap with systemic TFH‐derived lymphomas, underscoring the need for molecular work‐up and close clinical follow‐up to detect possible extracutaneous progression.